-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TZbn/9fwbk4Ig9KTzzw76s3ofAl+NhLJFEFi0XBurbQS8076eJF1Xc6vTH3pw02w LPnv0WlOZLnzaw8eS5rDVw== 0000855654-06-000021.txt : 20060510 0000855654-06-000021.hdr.sgml : 20060510 20060510130831 ACCESSION NUMBER: 0000855654-06-000021 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060505 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20060510 DATE AS OF CHANGE: 20060510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOGEN INC CENTRAL INDEX KEY: 0000855654 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042726691 STATE OF INCORPORATION: MA FISCAL YEAR END: 0606 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-17999 FILM NUMBER: 06824743 BUSINESS ADDRESS: STREET 1: 128 SIDNEY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6179952506 MAIL ADDRESS: STREET 1: 128 SIDNEY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 form8_k.htm IMMUNOGEN, INC. FORM 8-K ImmunoGen, Inc. Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported): May 5, 2006
 
ImmunoGen, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
 
 
Massachusetts
  
0-17999
  
04-2726691
(State or other
  
(Commission
  
(IRS Employer
jurisdiction of
  
File Number)
  
Identification No.)
incorporation)
        
 
 
 
 
 
128 Sidney Street, Cambridge, MA 02139
(Address of principal executive offices) (Zip Code)
 
 
 
 
 
Registrant’s telephone number, including area code: (617) 995-2500
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 

ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.

(a)  
Not applicable
(b)  
and (c)

Effective May 5, 2006, Karleen M. Oberton, Senior Corporate Controller and Principal Accounting Officer of ImmunoGen, Inc., has resigned her position to accept a position with another company.

Daniel M. Junius, the Company’s Senior Vice President, Finance and Chief Financial Officer, will serve as ImmunoGen’s Principal Accounting Officer effective immediately while ImmunoGen conducts a search for a new Corporate Controller. Mr. Junius has been with the Company since May 2005. Prior to joining ImmunoGen, Mr. Junius served as Executive Vice President and Chief Financial Officer of New England Business Service (NEBS) from 1998 until 2004. Prior to NEBS, Mr. Junius was Vice President and Chief Financial Officer at Nashua Corporation, which he joined in 1984 and held financial management positions of increasing responsibility before becoming Chief Financial Officer in 1996. Mr. Junius has entered into no transactions with ImmunoGen of the kind that would require disclosure under Item 404(a) of Regulation S-K.
As previously disclosed, Mr. Junius’ base salary is $300,000 per year, and he is eligible for an annual cash bonus of up to 35% of his annual salary. Mr. Junius is entitled to receive severance payments in an amount equal to twelve (12) months of his annual base salary in effect immediately prior to termination, in the event that his employment is terminated by the Company without cause.


(d) Not applicable

 
2
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
   
ImmunoGen, Inc.
  
   
(Registrant)
 
 
 
Date: May 10, 2006
  
/s/ Daniel M. Junius
  
 
 
 
   
Daniel M. Junius
   
Senior Vice President and Chief Financial Officer
     
 

 
3
 

 -----END PRIVACY-ENHANCED MESSAGE-----